Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity.

Saved in:
Bibliographic Details
Title: Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity.
Authors: Wantoch M; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Wilson EB; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Droop AP; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Phillips SL; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Coffey M; Oncolytics Biotech Inc, Calgary, Alberta, Canada., El-Sherbiny YM; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Holmes TD; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Melcher AA; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Wetherill LF; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Cook GP; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK.
Source: Immunology [Immunology] 2022 May; Vol. 166 (1), pp. 104-120. Date of Electronic Publication: 2022 Mar 09.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0374672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2567 (Electronic) Linking ISSN: 00192805 NLM ISO Abbreviation: Immunology Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Be the first to leave a comment!
You must be logged in first